Company intelligence / Profile preview

LeapFrog Enterprises

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Leapfrog Bio is an early-stage biotechnology company focused on the development of next-generation precision medicines for cancer. The company utilizes a proprietary platform to identify and exploit synthetic lethal genetic interactions, targeting specific vulnerabilities in tumor cells that are otherwise difficult to treat. By focusing on genetically defined patient populations, Leapfrog Bio aims to create highly effective therapies with improved safety profiles compared to traditional chemotherapy. The company is currently advancing its discovery-stage programs toward lead optimization and IND-enabling studies.

Therapeutic areas: Oncology
Modalities: Small moleculeTargeted therapy
Industry: Biotech

Beyond the preview

Go deeper on LeapFrog Enterprises.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LeapFrog Enterprises.

Explore the full profile